Buprenorphine Antibody – Mouse Monoclonal

Buprenorphine (or colloquially, "Bupe") is a semi-synthetic opiate with partial agonist and antagonist actions. Buprenorphine hydrochloride was first marketed in the 1980s by Reckitt & Colman (now Reckitt Benckiser) as an analgesic, available generally as Temgesic 0.2mg sublingual tablets, and as Buprenex in a 0.3mg/ml injectable formulation. In October 2002, the Food and Drug Administration (FDA) of the United States of America additionally approved Suboxone and Subutex, buprenorphine's high-dose sublingual pill preparations for opioid addiction, and as such the drug is now also used for this purpose. In the USA, it has been a Schedule III drug under the United Nations' Convention on Psychotropic Substances[1] since it was rescheduled from Schedule V (the schedule with the lowest restrictions and penalties in the USA) just before FDA approval of Suboxone and Subutex. In the recent years, buprenorphine has been introduced in most European countries as a transdermal formulation ("patch") for the treatment of chronic pain.

Small volumes of anti-Buprenorphine antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS606527 is an antibody targeting Buprenorphine. Also known as Buprenorphine (BUP) (BSA). Host: Mouse.